List of Excipients in Branded Drug CINACALCET

Generic Drugs Containing CINACALCET

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	CROSPOVIDONE
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	HYPROMELLOSE
Mylan Pharmaceuticals Inc	cinacalcet	0378-6197	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CINACALCET?

# Of NDCs	Excipient
1	ASCORBIC ACID
7	CARNAUBA WAX
36	CELLULOSE, MICROCRYSTALLINE
40	CROSPOVIDONE
35	FD&C BLUE NO. 2
2	FD&C BLUE NO. 2 ALUMINUM LAKE

Cinacalcet Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Cinacalcet is a mature, genericized small-molecule drug with limited opportunity for premium excipient innovation in conventional immediate-release tablets. The strongest commercial opportunities are in formulation improvements that address food dependence, swallowing difficulty, dose flexibility, adherence, and supply-chain economics. Cinacalcet hydrochloride is highly potent, poorly soluble, and administered in low doses, making blend uniformity, dissolution control, content uniformity, and taste management more important than simply increasing drug loading.

The primary product, Sensipar in the United States and Mimpara in Europe, is approved for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy [1]. Generic competition has materially reduced the value of the original tablet formulation, but the drug’s continuing use in dialysis creates opportunities for lower-cost excipient systems and differentiated oral dosage forms.

What is the commercial status of cinacalcet?

Cinacalcet hydrochloride is an established oral calcimimetic with broad generic availability in the United States and other major markets.

Attribute	Cinacalcet
Active ingredient	Cinacalcet hydrochloride
Reference product	Sensipar
Original sponsor	Amgen
Main dosage forms	Immediate-release tablets
Common strengths	30 mg, 60 mg, 90 mg
Primary market	Secondary hyperparathyroidism in dialysis patients
Other indications	Parathyroid carcinoma; severe hypercalcemia in primary hyperparathyroidism
Regulatory category	Small-molecule prescription drug
Biosimilar exposure	None
Generic pathway	ANDA, with potential Paragraph IV litigation
Key formulation constraint	Food-dependent exposure and low aqueous solubility

Sensipar generated more than $1 billion in annual sales during its peak commercial period before generic erosion. Amgen reported Sensipar product sales of approximately $1.5 billion in 2018, reflecting the size of the pre-generic opportunity [2]. Generic entry shifted commercial value from branded product sales toward manufacturing efficiency, hospital and dialysis-provider contracts, and differentiated dosage forms.

Cinacalcet remains commercially relevant because dialysis patients often require chronic treatment, the drug has an established clinical role, and treatment decisions are influenced by pill burden, tolerability, renal-care protocols, and reimbursement.

What excipients are used in commercial cinacalcet tablets?

The Sensipar formulation uses a conventional immediate-release tablet platform based on microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating polymers, pigments, and opacifying agents [1].

Reference-product excipient architecture

Formulation function	Typical excipient category	Role in cinacalcet tablets
Dilution and compression	Microcrystalline cellulose	Supports tablet mass and mechanical strength
Binder	Povidone	Improves granule and tablet cohesion
Disintegration	Crospovidone	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate	Reduces ejection friction
Film coating	Hypromellose-based system	Protects tablet and controls appearance
Color identification	Iron oxides and other pigments	Differentiates 30 mg, 60 mg, and 90 mg strengths

The formulation is commercially rational for a high-volume generic because it uses widely available, compendial excipients with established pharmaceutical use. The principal development risks are not regulatory novelty but low-dose uniformity, powder segregation, dissolution variability, and the potential for excessive hydrophobicity from over-lubrication.

Why is excipient selection important for cinacalcet?

Cinacalcet has low aqueous solubility and its exposure is strongly affected by food. The FDA label states that administration with food increases cinacalcet exposure, with a high-fat meal producing substantially higher exposure than administration under fasting conditions [1]. The label instructs patients to take cinacalcet with food or shortly after a meal.

This creates three formulation priorities:

1. Maintain reliable release despite variable gastric conditions.
2. Avoid adding further food dependence through poorly wetting or overly hydrophobic excipients.
3. Improve administration consistency for patients receiving chronic dialysis care.

Cinacalcet has high potency relative to the tablet dose. A 30 mg tablet may contain a relatively small proportion of active ingredient compared with the total tablet mass. Direct compression can be attractive, but powder flow and content uniformity must be demonstrated across commercial-scale batches. Wet granulation may improve uniformity and compressibility but can increase process complexity and exposure to moisture.

Formulation risks associated with common excipients

Magnesium stearate requires tight control because excessive concentration or prolonged blending can reduce wettability and slow dissolution. Crospovidone can improve disintegration, but performance depends on particle size, intragranular versus extragranular addition, and tablet porosity. Povidone selection affects granule strength and residual moisture. Colloidal silicon dioxide improves flow but may alter compaction behavior if used at excessive levels.

A generic developer should treat excipient grade and processing parameters as part of the product design. Substitution between grades from different suppliers can change bulk density, lubrication behavior, disintegration, and dissolution even when the nominal excipient identity remains the same.

What excipient strategies can improve cinacalcet bioavailability?

The strongest technical opportunity is to improve dissolution and reduce variability without materially changing the approved route or clinical use.

Particle-size reduction and wetting systems

Micronized cinacalcet hydrochloride can increase surface area and improve dissolution. The approach must control electrostatic charging, agglomeration, and segregation during blending. Colloidal silicon dioxide, low-substituted hydroxypropyl cellulose, or selected surfactants may improve powder handling and wetting.

Surfactant use requires caution. Sodium lauryl sulfate, polysorbates, and poloxamers can improve dissolution, but the benefit must be balanced against tablet stability, taste, gastrointestinal tolerance, and regulatory justification. A surfactant system is more attractive where dissolution is otherwise sensitive to particle-size changes or manufacturing scale.

Amorphous solid dispersions

Polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose, and hydroxypropyl methylcellulose acetate succinate can stabilize amorphous drug forms and improve apparent solubility. This strategy is technically credible but may be commercially excessive for a low-margin generic unless it produces a clear benefit such as reduced food dependence or a differentiated dosage form.

Key risks include recrystallization, moisture sensitivity, residual solvent control, and physical instability during long-term storage. A solid dispersion can also create a new patent position if the polymer ratio, process, or solid-state form is novel.

Lipid-based systems

Self-emulsifying or lipid-based systems may improve dissolution of a poorly soluble active ingredient. For cinacalcet tablets, the approach is less attractive because the reference product is a conventional solid oral dosage form and the drug already has a clinically relevant food effect. A lipid system that increases exposure could create dose-proportionality and safety questions.

Lipid excipients are more suitable for a softgel, oral suspension, or specialty formulation than for a low-cost generic tablet.

What formulation opportunities exist beyond standard tablets?

The most commercially credible opportunities are orally disintegrating, sprinkle, suspension, and flexible-dose products. Each requires a clear clinical or operational rationale.

Orally disintegrating tablets

An orally disintegrating tablet could serve dialysis patients with dysphagia, high pill burden, or difficulty taking medication during treatment. Mannitol, crospovidone, copovidone, and low-moisture manufacturing systems are relevant excipient choices.

The formulation must manage cinacalcet’s bitter taste. Suitable approaches include polymeric taste-masking coatings, ion-exchange resins, lipid barriers, and coated drug particles. Taste masking is essential because cinacalcet is administered chronically and may be exposed in the oral cavity.

Oral granules or sprinkle formulation

A granule or sprinkle formulation could provide dose flexibility and facilitate administration to patients who cannot swallow tablets. Possible excipient platforms include microcrystalline cellulose, mannitol, hypromellose, ethylcellulose, and polymer-coated drug particles.

The product must establish acceptable dosing accuracy when dispersed in soft food or liquid. Compatibility with enteral feeding systems would create a separate commercial opportunity, but this would require dedicated administration and stability studies.

Oral suspension

A ready-to-use or powder-for-reconstitution suspension could address patients with swallowing limitations. Suspending agents could include xanthan gum, microcrystalline cellulose-carboxymethylcellulose, hydroxypropyl cellulose, or poloxamer systems. Preservatives and buffer selection would depend on the intended shelf life and container system.

Suspensions introduce physical stability, redispersibility, microbial control, dose-measuring, and container-closure risks. The opportunity is stronger for specialty pharmacies, pediatric or institutional settings, and markets with limited access to tablets than for mass-market generic distribution.

Modified-release products

Modified-release cinacalcet has weaker commercial logic. The reference product is immediate release, and the main market consists of patients already managed through dialysis-centered care. A sustained-release formulation would require evidence that smoother exposure improves tolerability, adherence, parathyroid hormone control, or administration convenience.

Hydrophilic matrices using hypromellose or polyethylene oxide could control release, while ethylcellulose or methacrylate polymers could provide membrane-based systems. The development cost and regulatory burden would be difficult to justify without a meaningful clinical or payer advantage.

What patents protect cinacalcet formulations?

The original cinacalcet patent estate centered on the active compound and calcimimetic chemistry rather than on a broad, durable excipient platform. The principal historical U.S. patent associated with cinacalcet chemistry is U.S. Patent No. 6,211,244, assigned to Amgen-related entities and directed to calcimimetic compounds [3].

The original composition-of-matter protection has expired, subject to applicable patent-term adjustments and pediatric extensions. The commercial product has therefore moved into a generic market. New formulation patents remain possible, but they would need to claim a technically specific and non-obvious combination, such as:

• A defined amorphous cinacalcet dispersion with a stabilizing polymer.
• A taste-masked particle system with controlled release of the active ingredient.
• A specific excipient ratio that improves dissolution under fed and fasted conditions.
• A dosage form with demonstrated dose uniformity at low drug loading.
• A suspension with defined particle-size, redispersibility, and stability characteristics.
• A manufacturing process that produces a distinctive solid-state form or impurity profile.

Broad claims covering ordinary use of microcrystalline cellulose, povidone, crospovidone, and magnesium stearate are unlikely to create meaningful exclusionary value. Patent strength will depend on comparative data showing a measurable technical effect.

What is the Orange Book and Paragraph IV status of cinacalcet?

Cinacalcet is a small-molecule drug and is subject to the ANDA framework rather than the biosimilar pathway. Generic applicants may certify against listed patents under Paragraph IV and can trigger litigation under the Hatch-Waxman framework.

The practical legal position is:

Issue	Cinacalcet position
Regulatory route	ANDA for conventional generic tablets
Paragraph IV relevance	Historical and potentially relevant to new listed formulation patents
Reference product exclusivity	Expired
Composition-of-matter protection	Expired
Biosimilar pathway	Not applicable
Formulation patent risk	Depends on any currently listed or newly issued claims
Method-of-use risk	Relevant if a generic label overlaps protected indications or dosing instructions

Method-of-use patents can create narrower risks than composition patents. A generic applicant may attempt a section viii carve-out for a patented indication, but the feasibility depends on the wording of the reference label and the scope of the claims. A new formulation applicant must also assess whether its proposed label, dosing instructions, or administration method overlaps any remaining use claims.

The original Sensipar litigation and generic settlements reduced uncertainty around market entry, but the commercial impact of those agreements was primarily historical. Current diligence should focus on listed patents for the specific jurisdiction, pending continuation applications, and any formulation or method-of-use claims directed to a proposed differentiated product.

Which companies compete in the cinacalcet market?

Competition exists at three levels.

Generic cinacalcet manufacturers

Generic competition includes major multinational generic companies, regional manufacturers, and specialty suppliers. The competitive variables are:

• Lowest tablet cost.
• Reliable API supply.
• Consistent dissolution and content uniformity.
• Availability of 30 mg, 60 mg, and 90 mg strengths.
• Contracting access to dialysis providers.
• Regulatory approvals across the United States, Europe, Japan, and emerging markets.

Competing calcimimetics

Etelcalcetide is an injectable calcimimetic administered intravenously in hemodialysis settings. Evocalcet is an oral calcimimetic used primarily in Japan. These products compete with cinacalcet based on route of administration, adherence, gastrointestinal tolerability, parathyroid hormone control, and dialysis-center workflow [4].

Product	Route	Main commercial distinction
Cinacalcet	Oral tablet	Established, generic, flexible outpatient administration
Etelcalcetide	Intravenous	Dialysis-center administration and reduced oral pill burden
Evocalcet	Oral tablet	Alternative oral calcimimetic, principally Japanese market

Cinacalcet’s excipient opportunity is strongest where the product can reduce the disadvantages of oral administration without approaching the cost or operational model of an injectable product.

How strong is the patent estate for a new cinacalcet formulation?

A new cinacalcet formulation can have moderate patent strength if it combines a defensible composition with clinical or performance data. The estate is weak when it relies on routine excipient substitution.

Higher-value claim strategies

A stronger patent program would focus on:

1. A defined solid-state or amorphous form with reproducible characterization.
2. A specific polymer-drug ratio linked to enhanced dissolution.
3. A taste-masked multiparticulate system with release data.
4. A dosage form that reduces food-effect variability.
5. A process claim tied to particle engineering and content uniformity.
6. A clinically useful lower-pill-burden or flexible-dose system.

Lower-value claim strategies

Weak claims are more likely where they cover:

• A conventional film-coated tablet.
• Standard excipient combinations without comparative evidence.
• Broad use of mannitol, cellulose, povidone, or magnesium stearate.
• Routine changes in tablet color, hardness, or coating thickness.
• A formulation that improves dissolution only under nonrepresentative test conditions.

Patent protection should be supported by fed-versus-fasted pharmacokinetic data, dissolution profiles across pH conditions, stability data, and direct comparison with Sensipar or a leading generic.

What regulatory issues affect cinacalcet excipient innovation?

For a conventional generic tablet, FDA review will focus on pharmaceutical equivalence, bioequivalence, quality, stability, dissolution, impurities, and manufacturing controls. An excipient change does not automatically create a new product category, but a novel excipient or materially different dosage form can increase regulatory burden.

Key FDA considerations

• Bioequivalence under the applicable product-specific guidance.
• Fed and fasted performance where food materially changes exposure.
• Dissolution method sensitivity and discriminatory capability.
• Content uniformity at 30 mg strength.
• Impurity and degradation-product control.
• Excipient safety and precedent of use.
• Tablet robustness during packaging and transport.
• Labeling consistency across strengths.
• In vitro and in vivo performance for taste-masked or multiparticulate products.

A 505(b)(2) strategy may be appropriate for a differentiated dosage form that cannot rely fully on ANDA equivalence. That route can support an oral suspension, orally disintegrating product, or modified formulation, but it requires a stronger justification for clinical relevance and may face greater development expense.

What commercial opportunities exist by geography?

The United States offers scale but has intense generic price competition. Europe has fragmented national procurement and reimbursement, which can reward supply reliability and differentiated administration formats. Japan is strategically relevant because evocalcet creates a more developed calcimimetic market and local clinical preferences may support alternative oral products. Emerging markets may favor low-cost tablets but present opportunities for robust, heat-stable products and simpler packaging.

Geography	Best-fit opportunity
United States	Low-cost generic, ODT, specialty-pharmacy formulation
European Union	Generic supply contracts, dysphagia-focused products
Japan	Differentiated oral formulation and local licensing
Middle East and Latin America	Stable, low-cost multi-strength tablets
India and Southeast Asia	API-linked manufacturing and regional generic supply

Licensing opportunities are more likely to involve a formulation platform, regional commercialization rights, or manufacturing capacity than the original cinacalcet molecule. A company with taste-masking, amorphous-dispersion, or multiparticulate technology could license a cinacalcet product to a generic manufacturer with established dialysis-channel access.

What manufacturing and IP barriers remain?

The active pharmaceutical ingredient is commercially available, so API exclusivity is no longer the main barrier. The more relevant barriers are:

• Consistent low-dose blend uniformity.
• Control of polymorphism and particle-size distribution.
• Dissolution reproducibility after scale-up.
• Supplier qualification for functional excipient grades.
• Protection against moisture and mechanical stress.
• Taste masking without delayed or incomplete release.
• Bioequivalence when the formulation changes food sensitivity.
• Contracting and distribution through dialysis networks.

A differentiated product must produce enough economic value to offset formulation, clinical, regulatory, and manufacturing costs. For standard tablets, the opportunity is primarily cost leadership. For ODTs, suspensions, and sprinkle products, the opportunity is margin expansion through patient convenience and channel differentiation.

Key Takeaways

• Cinacalcet is a mature small-molecule drug with expired original exclusivity and established generic competition.
• Conventional excipient innovation has limited value unless it improves dissolution, content uniformity, food-effect consistency, or manufacturing cost.
• The most credible differentiated products are orally disintegrating tablets, taste-masked multiparticulates, sprinkle formulations, and oral suspensions.
• The reference tablet uses a conventional platform of microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, and film-coating excipients.
• A new patent estate should claim defined compositions, solid-state forms, particle systems, process controls, or demonstrated reductions in food-effect variability.
• Cinacalcet has no biosimilar pathway because it is a small molecule.
• Generic competition is strongest in standard tablets; commercial whitespace is greater in dysphagia, dose-flexibility, and dialysis-administration products.
• The largest technical risks are low-dose uniformity, dissolution control, taste, stability, and bioequivalence after excipient changes.

FAQs

Can cinacalcet be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but taste masking and exposure control are central development requirements because cinacalcet is bitter and food affects systemic exposure.

Which excipients are most suitable for taste masking cinacalcet?

Polymeric coatings, ion-exchange resins, ethylcellulose barriers, lipid systems, and coated multiparticulates are potential approaches. The selected system must preserve rapid release after swallowing.

Is a cinacalcet suspension commercially attractive?

It can be attractive for dysphagia, institutional use, and specialty pharmacy distribution. The main challenges are redispersibility, dose accuracy, microbial control, and stability.

Can a new cinacalcet formulation obtain patent protection?

Yes, if the formulation has a specific composition or manufacturing process supported by a non-obvious technical effect. Routine excipient substitution is unlikely to provide strong protection.

Does cinacalcet compete directly with etelcalcetide?

Yes. Both are calcimimetics used in dialysis-related care, but cinacalcet is oral and generic while etelcalcetide is administered intravenously in the dialysis setting. Their commercial positioning differs primarily by route, adherence, tolerability, and treatment workflow.

References

1. U.S. Food and Drug Administration. (2023). Sensipar (cinacalcet hydrochloride) tablets: Prescribing information.
2. Amgen Inc. (2019). 2018 annual report.
3. U.S. Patent No. 6,211,244. (2001). Calcimimetic compounds. U.S. Patent and Trademark Office.
4. U.S. Food and Drug Administration. (2018). Parsabiv (etelcalcetide) injection: Prescribing information.